Skip to search formSkip to main contentSkip to account menu

TP 9201

Known as: L-Cysteinamide, N-acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginylglycyl-L-alpha-aspartyl-O-methyl-L-tyrosyl-L-arginyl-, cyclic (1-9)-disulfide, TP-9201, TP9201 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cyclic Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
TP 9201
1997
1997
TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
BACKGROUND AND PURPOSE We examined the ability of TP-9201, a platelet glycoprotein IIb/IIIa receptor antagonist, to prevent… 
1996
1996
Inhibition of plasma‐mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD‐containing peptides
Adherence of sickle erythrocytes to vascular endothelium likely initiates or participates in microvascular occlusion, leading to… 
1996
1996
Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom.
1996
1996
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.
The effect of heparin, aspirin, and recombinat tissue-type plasminogen activator (rt-PA) on TP-9201 pharmacokinetics and… 
1995
1995
Pharmacokinetics and Pharmacodynamics of TP‐9201, a GPIIbIIIa Antagonist, in Rats and Dogs
Because activation of the glycoprotein IIbIIIa (GPIIbIIIa) on platelets represents the final common pathway of platelet… 
1995
1995
Determination of the pharmaceutical peptide TP9201 by post-column reaction with copper(II) followed by electrochemical detection.
Review
1995
Review
1995
Antiplatelet and antithrombotic agents
1994
1994
Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time.
Synthetic vascular prostheses lack the uniquely low thrombogenicity provided by the endothelial cell lining of autogenous… 
1993
1993
Inhibition of coronary artery reocclusion after thrombolysis with an RGD‐containing peptide with no significant effect on bleeding time
BackgroundA synthetic RGD-containing cyclic peptide, TP9201, specific for the platelet αIIbβ3 receptor complex, was tested for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)